Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan

Author:

Nakane Keita1ORCID,Taniguchi Kazuki2,Nezasa Minori3,Enomoto Torai13,Yamada Toyohiro4,Tomioka-Inagawa Risa5,Niwa Kojiro6,Tomioka Masayuki17,Ishida Takashi8,Nagai Shingo9,Yokoi Shigeaki10,Taniguchi Tomoki1ORCID,Kawase Makoto1ORCID,Kawase Kota1,Iinuma Koji1,Tobisawa Yuki1,Koie Takuya1ORCID

Affiliation:

1. Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan

2. Department of Urology, Gifu Prefectural General Medical Center, Gifu 5008717, Japan

3. Department of Urology, Matsunami General Hospital, Gifu 5016062, Japan

4. Department of Urology, Ogaki Municipal Hospital, Ogaki 5038502, Japan

5. Department of Urology, Japanese Red Cross Takayama Hospital, Takayama 5068550, Japan

6. Department of Urology, Daiyukai Daiichi Hospital, Ichinomiya 4918551, Japan

7. Department of Urology, Chuno Kosei Hospital, Seki 5013802, Japan

8. Department of Urology, Gifu Municipal Hospital, Gifu 5008513, Japan

9. Department of Urology, Toyota Memorial Hospital, Toyota 4718513, Japan

10. Department of Urology, Central Japan International Medical Center, Minokamo 5058510, Japan

Abstract

Randomized phase III trial results have demonstrated enfortumab vedotin (EV), an antibody–drug conjugate (ADC) consisting of an anti-Nectin-4 human IgG1 monoclonal antibody and monomethyl auristatin E, is a useful treatment for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) that progressed after immune checkpoint inhibitor (ICI) therapies. This multicenter retrospective cohort study aimed to identify predictive factors for the efficacy of EV therapy and prolonged overall survival (OS) of patients in clinical practice. This study included patients with la/mUC who received ICI treatment. Patients who subsequently received EV treatment, those who received non-EV chemotherapy, and those who received no treatment were defined as EV, non-EV, and best supportive care (BSC) groups, respectively. The median OS was 20, 15, and 7 months in the EV, non-EV, and BSC groups, respectively (p < 0.001). Patients with la/mUC who had a complete or partial response after EV treatment had a significantly prolonged OS compared with those with stable or progressive disease. Univariate analysis showed age, neutrophil-to-lymphocyte ratio (NLR), dysgeusia, and rash as independent predictors of OS improvement. NLR and dysgeusia were independent predictors of OS after EV in multivariate analysis. Patients without these factors had a significantly prolonged OS compared to those with both factors. In real-world practice, EV therapy is an effective treatment for patients with la/mUC after ICI treatment.

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3